David J. Mauro

2.7k total citations · 1 hit paper
26 papers, 2.0k citations indexed

About

David J. Mauro is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, David J. Mauro has authored 26 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in David J. Mauro's work include Colorectal Cancer Treatments and Studies (17 papers), Cancer Treatment and Pharmacology (6 papers) and Lung Cancer Treatments and Mutations (6 papers). David J. Mauro is often cited by papers focused on Colorectal Cancer Treatments and Studies (17 papers), Cancer Treatment and Pharmacology (6 papers) and Lung Cancer Treatments and Mutations (6 papers). David J. Mauro collaborates with scholars based in United States, Spain and South Korea. David J. Mauro's co-authors include Shirin Khambata‐Ford, Christopher Harbison, Edwin Clark, Eric K. Rowinsky, Andrew K. Godwin, José Baselga, Heinz‐Josef Lenz, Howard A. Burris, Tai W. Wong and Benjamin Tan and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

David J. Mauro

25 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

2007 898 citations Shirin Khambata‐Ford, Christopher R. Garrett et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by David J. Mauro

Since Specialization

Citations

This map shows the geographic impact of David J. Mauro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. Mauro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. Mauro more than expected).

Fields of papers citing papers by David J. Mauro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David J. Mauro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. Mauro. The network helps show where David J. Mauro may publish in the future.

Co-authorship network of co-authors of David J. Mauro

This figure shows the co-authorship network connecting the top 25 collaborators of David J. Mauro. A scholar is included among the top collaborators of David J. Mauro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David J. Mauro. David J. Mauro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Relationship between pre-treatment organ-specific tumor burden (TB) and response to immunotherapy in advanced melanoma (MEL). 2018 ·Journal of Clinical Oncology ·Ryan Massa, Mark C. Sparrow, Lin Huang, Yan Lin, David J. Mauro, (unknown), (unknown), Amy Rose, Yana G. Najjar, John M. Kirkwood, Diwakar Davar	2
2	A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer 2017 ·Breast Cancer Research and Treatment ·Hope S. Rugo, Olivier Trédan, Jungsil Ro, Serafín Morales, Mario Campone, Antonino Musolino, N. Afonso, M. Ferreira, Kyong Hwa Park, Javier Cortés, Antoinette R. Tan, Joanne L. Blum, Lamar Eaton, Christine K. Gause, Zhen Wang, Ellie Im, David J. Mauro, (unknown), Andrew Denker, José Baselga	21
3	Phase Ib trial of the CpG-A Oligonucleotide CMP-001 combined with pembrolizumab (Pembro) in patients with advanced melanoma. 2016 ·Journal of Clinical Oncology ·Mohammed Milhem, Hassane M. Zarour, Nashat Gabrail, David J. Mauro, Norman M. Greenberg, William J. Slichenmyer, Arthur Μ. Krieg	2
4	A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory,KRASWild-Type, Metastatic Colorectal Cancer 2015 ·JNCI Journal of the National Cancer Institute ·Francesco Sclafani, Tae‐Yop Kim, David Cunningham, Tae W. Kim, Josep Tabernero, Hans‐Joachim Schmoll, Jae Kyung Roh, Sun Kim, Young Shin Park, Tormod Kyrre Guren, Eliza A. Hawkes, (unknown), David Ferry, Jan‐Erik Frödin, Mark Ayers, Michael Nebozhyn, Clare Peckitt, Andrey Loboda, David J. Mauro, David Watkins	73
5	BATLLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC). 2014 ·Journal of Clinical Oncology ·Vassiliki A. Papadimitrakopoulou, J. Jack Lee, Ignacio I. Wistuba, Anne S. Tsao, Frank V. Fossella, John V. Heymach, Neda Kalhor, Sanjay Gupta, Scott Gettinger, Lauren A. Byers, Julie Izzo, Vincent A. Miller, Lixia Diao, Jing Wang, Caimiao Wei, Kevin R. Coombes, David J. Mauro, Eric H. Rubin, Waun Ki Hong, Roy S. Herbst	3
6	BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC). 2013 ·Journal of Clinical Oncology ·Vassiliki A. Papadimitrakopoulou, Ignacio I. Wistuba, J. Jack Lee, Anne S. Tsao, Neda Kalhor, Frank V. Fossella, John V. Heymach, Christine Alden, Scott Gettinger, Kevin R. Coombes, Pierre Saintigny, Ximing Tang, (unknown), Julie L. Boyer, Suzanne E. Davis, Garth Powis, David J. Mauro, Eric H. Rubin, Waun Ki Hong, Roy S. Herbst	3
7	Tumor IGF-1 expression as a predictive biomarker for IGF1R-directed therapy in advanced pancreatic cancer (APC). 2012 ·Journal of Clinical Oncology ·Milind Javle, Rachna T. Shroff, Gauri R. Varadhachary, Robert A. Wolff, David R. Fogelman, Priya Bhosale, Xuemei Wang, Siddhartha Kar, Michael J. Overman, Sriram Sathyanarayanan, Mark Ayers, David J. Mauro, James L. Abbruzzese	5
8	Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer 2011 ·British Journal of Cancer ·Joffre Baker, Debjani Dutta, Drew Watson, Tara Maddala, Brian Munneke, S. Shak, (unknown), (unknown), Christopher Harbison, Edwin Clark, David J. Mauro, Shirin Khambata‐Ford	81
9	Human epidermal growth factor receptor-2 (HER2) Ile655Val single nucleotide polymorphism (SNP) is associated with gender-specific outcome in patients with metastatic colorectal cancer (mCRC) treated with cetuximab in a phase II study (IMCL-0144). 2011 ·Journal of Clinical Oncology ·Armin Gerger, Pierre Bohanes, Dawei Yang, Thomas Winder, Yan Ning, Melissa J. LaBonte, David J. Mauro, Christiane Langer, Eric K. Rowinsky, H.J. Lenz	3
10	Comprehensive analysis of potential predictive biomarkers for insulin-like growth factor type-1 receptor (IGF-1R) targeted therapy in pancreatic cancer. 2011 ·Journal of Clinical Oncology ·Rachna T. Shroff, M. M. Javle, (unknown), Robert A. Wolff, David J. Mauro, George N. Naumov, Michael Nebozhyn, (unknown), (unknown), (unknown)	1
11	Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients 2010 ·Clinical Cancer Research ·Thomas Winder, Wu Zhang, Dongyun Yang, Yan Ning, Pierre Bohanes, Armin Gerger, Peter M. Wilson, Alexandra Pohl, David J. Mauro, Christiane Langer, Eric K. Rowinsky, Heinz‐Josef Lenz	43
12	A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy 2010 ·Annals of Oncology ·(unknown), Thomas Winder, Yan Ning, (unknown), Dongyun Yang, Michael Kahn, Georg Lurje, Melissa J. LaBonte, P. M. Wilson, Michael A. Gordon, Siwen Hu‐Lieskovan, David J. Mauro, Christiane Langer, Eric K. Rowinsky, Heinz‐Josef Lenz	107
13	Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice 2009 ·Cancer Research ·David Surguladze, Dhanvanthri S. Deevi, (unknown), Erik Corcoran, Su Wang, Mary Jane Plym, Yan Wu, Jacqueline Doody, David J. Mauro, Larry Witte, Klaus J. Busam, (unknown), Ulrich Rodeck, James R. Tonra	40
14	Evaluation of tumor gene expression and K-Ras mutations in FFPE tumor tissue as predictors of response to cetuximab in metastatic colorectal cancer 2008 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Tara Maddala, S. Shak, Eric K. Rowinsky, Lei Xu, (unknown), David J. Mauro, Shirin Khambata‐Ford	8
15	Polymorphisms inCyclooxygenase-2andEpidermal Growth Factor ReceptorAre Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab 2008 ·Clinical Cancer Research ·Georg Lurje, Fumio Nagashima, Wu Zhang, Dongyun Yang, Heung Moon Chang, Michael A. Gordon, Anthony B. El-Khoueiry, Hatim Husain, Peter M. Wilson, Robert D. Ladner, David J. Mauro, Christiane Langer, Eric K. Rowinsky, Heinz‐Josef Lenz	93
16	In Reply 2008 ·Journal of Clinical Oncology ·Christopher Harbison, David J. Mauro, Edwin Clark, Shirin Khambata‐Ford	5
17	Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab breakdown → 2007 ·Journal of Clinical Oncology ·Shirin Khambata‐Ford, Christopher R. Garrett, Neal J. Meropol, Mark Basik, Christopher Harbison, Shujian Wu, Tai W. Wong, Xin Huang, Chris H. Takimoto, Andrew K. Godwin, Benjamin Tan, Smitha Krishnamurthi, Howard A. Burris, Elizabeth Poplin, Manuel Hidalgo, José Baselga, Edwin Clark, David J. Mauro	898
18	Impact and Management of Skin Toxicity Associated with Anti-Epidermal Growth Factor Receptor Therapy: Survey Results 2007 ·Oncology ·Susan L. Boone, Alfred Rademaker, Dachao Liu, (unknown), David J. Mauro, Mario E. Lacouture	139
19	Preclinical discovery and clinical validation of predictive markers of response to cetuximab (Erbitux™) in metastatic colorectal cancer 2006 ·Cancer Research ·(unknown), (unknown), Xin Huang, Tai W. Wong, Suso Platero, Christiane Langer, (unknown), Lynn Ploughman, Edwin Clark, David J. Mauro	3
20	Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines 2006 ·Journal of Clinical Oncology ·Heinz‐Josef Lenz, Eric Van Cutsem, Shirin Khambata‐Ford, Robert J. Mayer, Philip J. Gold, Philip J. Stella, B. Mirtsching, Allen Lee Cohn, Andrew W. Pippas, N. Azarnia, Zenta Tsuchihashi, David J. Mauro, Eric K. Rowinsky	420

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact